\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
HENDERSON, N. C. , July 29, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multinational epigenetics company, announced the value of its subscribed audience by providing 3,000,000 non-unusual shares at a provision value of $2. 00 consistent with the share. Volition’s gross earnings from the Offering, prior to deduction of subscription fees and other estimated provisioning fees payable through Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the Offering a one-day option to acquire up to 450,000 additional non-unusual shares at the Tender Offer Price, less discounts and subscription commissions, to cover over-allocations under the Offering. The Offering is expected to close on or around August 2, 2022, satisfying the standard final conditions.
Volition intends to use the proceeds from the provision for ongoing product studies and development, clinical studies, product commercialization, operating capital and other general corporate objectives, in addition to potential strategic acquisitions.
Newbridge Securities Corporation is the only book broker in the offering.
The securities are being presented through Volition pursuant to a “pending” filing on Form S-3 (File No. 333-259783) filed in the past with the Securities and Exchange Commission (the “SEC”) on December 24, September 2021 and declared effective through the SEC on November 8, 2021. The provision is made only through a supplemental prospectus and the attached base prospectus, which would possibly be supplemented through any loose written prospectus and/or price. supplement that the Company may file with the SEC. A supplement to the initial prospectus and an accompanying base prospectus that describe the terms of the proposed supply have been filed with the SEC and are available on the SEC’s website at www. sec. gov. Copies of the initial prospectus supplement and accompanying base prospectus relating to the provision may also be obtained, where possible, from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400 Array Boca Raton, FL 33432, via email at syndicate@newbridgesecurities. com or by phone at (877) 447-9625. The final terms of the provision will be disclosed in a supplement to the final prospectus to be filed with the SEC.
This press release constitutes an offer to sell or the solicitation of an offer to purchase such securities, and there will be no sale of such securities in any state or other jurisdiction in which such offer, solicitation or sale is made. be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Will
Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to expand simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a variety of life-changing diseases, including certain cancers and associated diseases. with NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the perspective not only of prolonging the life of patients, but also of their quality of life. The tests are based on nucleosomics™ science, which is the practice of identifying and measuring nucleosomes in the bloodstream or other physical fluids, an indication that disease is present. Volition basically focuses on human diagnosis and monitoring, but also has a subsidiary aimed at animal diagnosis and monitoring.
Volition’s studies and progression activities focus on Belgium, with an innovation lab and on the United States and more in London and Singapore.
Cautionary Note On Forward-Looking Statements
Statements contained in this press release would possibly be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to with matters involving dangers and uncertainties that may also cause actual effects to differ materially from those expected or projected in forward-looking statements. These forward-looking statements reflect the existing ideals and expectations of management and come with statements regarding the timing, duration and expected gross receipts of the supply, the anticipated use of the proceeds of the supply, the satisfaction of end situations related standard cases with the supply and sale of securities, the granting to the underwriter of an option to acquire further shares, and Volition’s ability to complete the offering. All statements other than statements of past fact are statements that may also be considered forward-looking statements. Although Volition believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee that those expectations will prove to be correct. Forward-looking statements are subject to dangers and uncertainties that could possibly cause Volition’s actual operations or effects to differ materially from those indicated or implied by any forward-looking statement, including, but not limited to, due to dangers and uncertainties related to market and the satisfaction of final situations related to the proposed public provision, the dangers disclosed in the segment entitled “Risk Factors” are included in the initial prospectus supplement filed with the SEC on July 28, 2022, and the dangers disclosed in other documents Volition files from time to time with the SEC, adding Volition’s quarterly reports on Form 10-Q and its annual report on Form 10-K. Forward-looking statements are made as of the date of this release and, as required by law, Volition does not adopt the updating of its forward-looking statements to reflect long-term events or occasions.
Nucleosomics™ and Nu. Q® and their respective logos are and/or service marks of VolitionRx Limited and its subsidiaries.
Media
Louise Batchelor/Debra DaglishVolitionmediarelations@volition. com (0)7557 774620
Investors
Scott PowellVolitioninvestorrelations@volition. com 1 (646) 650-1351
Joseph GreenAdvisors Edisonjgreen@edisongroup. com 1 (646) 653-7030
View Content: https://www. prnewswire. com/news-releases/volitionrx-limited-announces-pricing of-6-million-underwriter-public-offering-of-common-stock-301596094. html
SOURCE VolitionRx Limited